- Home
- WHF vs BDTX Comparison
WHF vs BDTX Comparison
Compare WHF & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WHF | BDTX |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 171.9M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WHF | BDTX |
|---|---|---|
| Price | $7.08 | $1.95 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.75 | ★ $9.67 |
| AVG Volume (30 Days) | 78.7K | ★ 464.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 13.67% | N/A |
| EPS Growth | 31.91 | ★ 130.71 |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.07 | $1.60 |
| 52 Week High | $7.87 | $4.94 |
Technical Indicators
Market Signals| Indicator | WHF | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 42.52 |
| Support Level | $7.08 | $1.61 |
| Resistance Level | $7.22 | $2.28 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 25.61 | 9.78 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.